Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS) is a major international research project. It aims to develop new ways of measuring major depressive disorder (MDD), epilepsy and multiple sclerosis (MS) using wearable devices and smartphone technology.
RADAR-CNS aims to improve people’s quality of life and change how depression, epilepsy and MS are managed and treated. Data from mobile devices can give a full picture of a person’s condition at a level of detail which was previously impossible. This offers the potential to detect changes in behaviour, sleep, or mood before the individual themselves is aware of it. This could help them to predict – or even avoid – a relapse.
RADAR-CNS brings together clinicians, researchers, engineers, computer scientists and bioinformaticians from all over the world. It is jointly led by King’s College London and Janssen Pharmaceutica NV. It includes 23 organisations from across Europe and the US. The RADAR-CNS project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (www.imi.europa.eu).
In Amsterdam, we take part in the depression study of RADAR-CNS. 600 people who have experienced a depressive episodes will participate in this study, with data being collected through smartphone apps and data from a Fitbit in three countries (UK, Spain, Netherlands).
Femke Lamers (project leader RADAR-CNS Amsterdam) or Sonia Difrancesco (PhD student)